The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...

Explore the latest advancements in denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases in ...

Biosimilar development costs could plummet from $100 million to $5 million, enabling smaller companies to enter the market ...

In 2025, the latest biosimilar policy developments included bipartisan efforts to enhance affordability and reduce barriers ...

A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab ...